Neuroendocrine tumours have a number of different classification and staging systems. I will present the latest of these, which include the latest WHO system with the implications for new entities and how they are diagnosed pathologically and any difficulties that arise from this. There will also be a more general discussion about areas that are difficult for the pathologist and where we can add value to the MDT discussion.
04 Dec 2017
UK and Ireland Neuroendocrine Tumour Society